FDA advisers to vote on Grail's multi-cancer blood test approval
An independent panel of experts will decide if the Galleri blood test should be recommended for FDA approval.
How it unfolded
Every source in the order it published.
- STATSTAT+: What a vote on Grail’s cancer detection test could mean for the company, patients, and regulators
- NPR HealthWill FDA advisers recommend a multi-cancer blood test for approval? They'll vote
- MarketWatchFDA advisers are reviewing a multicancer-detection test. Medicare coverage could follow.
- QuartzFDA advisers are voting on Grail's multicancer blood test as Medicare coverage hangs in the balance
Sources
Every article we clustered into this story. Headlines link to the publisher.
- Will FDA advisers recommend a multi-cancer blood test for approval? They'll vote NPR Health ·
- FDA advisers are voting on Grail's multicancer blood test as Medicare coverage hangs in the balance Quartz
- FDA advisers are reviewing a multicancer-detection test. Medicare coverage could follow. MarketWatch
- STAT+: What a vote on Grail’s cancer detection test could mean for the company, patients, and regulators STAT
In this story
- FDA
- Grail